Seth Cheetham

The greatest challenge for #mRNA-LNP therapies is targeting non-liver tissues. To overcome this, we used customisable bispecific antibodies to tether mRNA-LNPs to cell-surface proteins, achieving efficient and selective mRNA delivery in vivo. @BASEmRNA

biorxiv.org/content/10.110…

To accelerate #mRNA vaccine and therapy research, I'm excited to share our end-to-end protocol for #mRNA design, synthesis and encapsulation in
@NatureProtocols.

Protocol development by @LauraJLeighton, Natasha Chaudhary and Tim Mercer. @BASEmRNA

nature.com/articles/s4159…

A huge milestone for personalised #mRNA therapeutics for inherited disease! A baby with an ultra-rare mitochondrial disease was treated at UPenn with an mRNA-encoded gene-corrector. The mRNA was made to treat a single individual in just 7 months!

nejm.org/doi/full/10.10…

Systemic mRNA-LNP delivery beyond the liver? Check out our recent paper demonstrating cell-specific mRNA-LNP delivery using PEG- and target cell-specific antibodies. This approach can customised to any target cell-type with off-the-shelf mRNA-LNPs. 1/

sciencedirect.com/science/articl…

Exited to share our latest preprint! mRNA-LNPs are efficiently delivered to healthy livers, but what about liver tumours? Our postdoc Laura Leighton found liver tumours efficiently take up mRNA, enabling next generation mRNA-LNP cancer therapeutics.

biorxiv.org/content/10.110…